A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total Occlusions

Inclusion Criteria: * Adult aged 25-80 * Patient understands and has signed the study informed consent form. * Patient is a suitable candidate for non-emergent, coronary angioplasty * Patient has an angiographic documented Chronic Total Occlusion (i.e. \>3 months occlusion duration either by documentation or PI assessment Investigator) showing distal TIMI flow 0. * Coronary angiography of CTO lesion reveals satisfactory distal vessel visualization * CTO lesion is located in a coronary vessel with a reference diameter of at least 2 millimeters. * CTO lesion is suitable for antegrade approach. * Left ventricle ejection fraction \> 25% * Body Mass Index (BMI) \< 40 Exclusion Criteria: * Patient unable to give informed consent. * Patient is participating in another study with any investigational drug or device. * Patient is known or suspected not to tolerate the contrast agent. * Aorto-ostial CTO location (Ostial bifurcation origins may be considered), SVG CTO. * Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent (Clopidogrel and Prasugrel and Ticagrelor). * Appearance of a fresh thrombus or intraluminal filling defects. * Recent major cerebrovascular event (stroke or TIA within 30 days) * Significant anemia (hemoglobin \< 8.0 mg / dl) * Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) * Recent myocardial infarction (MI) (within the past two weeks) * Unwillingness or inability to comply with any protocol requirements * Pregnancy or nursing